Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Sumatriptan Metabolism Revisited: CYP and MAO Evidence
2026-10-06
Pöstges and Lehr revisited the accepted view that sumatriptan is metabolized mainly through monoamine oxidase A, showing that selected CYP enzymes also produce sequential N-desmethyl metabolites. Their recombinant-enzyme and HPLC-MS evidence supports a more flexible metabolic model, while its direct applicability to human pharmacokinetics remains limited.
Cannabidiol, Orofacial Pain, and Affective Recovery
2026-10-05
A 2026 Brain Research Bulletin study reports that cannabidiol (CBD) reduced acute and chronic inflammatory pain in mice while also improving pain-related affective and cognitive abnormalities. Its main innovation is a multi-level analysis linking peripheral inflammation, central pain circuits, endocannabinoid signaling, and serotonin activity without treating sensory analgesia as the only meaningful outcome.
CRISPR Repair Outcomes in Nondividing Cells
2026-10-05
A source-grounded overview of how nondividing human cells repair CRISPR-induced DNA damage, what the 2025 Nature Communications study found, and where its evidence does—and does not—support translational interpretation.
Palonosetron Hydrochloride: CINV and RINV Evidence
2026-10-04
The 2013 review by Fabi and Malaguti positioned palonosetron hydrochloride as a distinctive 5-HT3 receptor antagonist because its high receptor affinity and prolonged half-life may improve control of delayed chemotherapy-induced nausea and vomiting. Its main practical implication is evidence-based placement within antiemetic strategies, while also highlighting unresolved questions for radiotherapy, multi-day chemotherapy, and combination treatment.
Tropisetron Hydrochloride: A Receptor-to-Transporter View
2026-10-03
Tropisetron Hydrochloride is more than a 5-HT3 receptor antagonist: it offers a useful model for separating receptor pharmacology from renal transporter effects. This article interprets the compound’s dual pharmacology, the OCT2/MATE1 evidence, and the boundaries between in vitro findings and broader biological conclusions.
Perospirone: Receptor–Kv Assay Design
2026-10-02
Perospirone (SM-9018 free base) connects serotonergic and dopaminergic receptor pharmacology with a newly characterized vascular Kv1.5-associated effect. This assay-centered guide explains how to interpret the evidence, select models, and avoid overstating translational conclusions in schizophrenia research.
Perospirone: From Receptors to Kv1.5 Assays
2026-10-01
Perospirone links serotonergic and dopaminergic receptor pharmacology with a newly characterized vascular Kv1.5 effect. This guide shows how to design and interpret schizophrenia research and neurovascular assays without confusing affinity, efficacy, and off-target activity.
Tropisetron Hydrochloride: Assay Workflows
2026-10-01
Tropisetron Hydrochloride supports paired studies of 5-HT3 receptor pharmacology, α7-nicotinic signaling, and renal organic-cation transport. This workflow-focused guide translates receptor selectivity and OCT2/MATE1 inhibition data into practical assay design, controls, and troubleshooting decisions.
BMS 599626 dihydrochloride: EGFR/HER2 Workflow
2026-09-30
Use BMS 599626 dihydrochloride to separate EGFR/HER2 pathway dependence from generic cytotoxicity in cancer and senescence-aware assays. This workflow combines acute phospho-signaling measurements, longer-term proliferation studies, and matched senescent versus non-senescent controls for more interpretable results.
Clozapine in Schizophrenia Research Workflows
2026-09-30
Clozapine enables receptor-informed studies of antipsychotic pharmacology, ERK1/2 responses, and liver liability across cellular and animal models. Its broad systemic profile complements the spatial precision of magnetic stimulation studies targeting GABRE in the prelimbic cortex.
High-Throughput Surrogate BBB Model for CNS Screening
2026-09-29
Hu and colleagues developed a Transwell blood-brain barrier surrogate using LLC-PK1-MOCK and LLC-PK1-MDR1 cells, combining permeability measurements with correction for lysosomal drug trapping. The approach correlated in vitro transport with unbound brain distribution and offers a practical framework for prioritizing central nervous system candidates before extensive in vivo testing.
Tropisetron Hydrochloride: Assay Workflows
2026-09-29
Build a receptor-to-transporter workflow around Tropisetron Hydrochloride for serotonin receptor signaling research, neuroscience receptor modulation, and renal drug-interaction assays. The approach separates 5-HT3 pharmacology from OCT2/MATE1 transport effects so concentration-dependent findings are easier to interpret.
Perospirone Inhibits Coronary Kv1.5 Channels
2026-09-28
A 2025 Journal of Applied Toxicology study identifies a previously unrecognized vascular ion-channel action of Perospirone in freshly isolated rabbit coronary arterial smooth muscle cells. The findings connect an established serotonergic and dopaminergic antipsychotic mechanism with concentration-dependent, use-independent inhibition of vascular Kv currents, while emphasizing that the evidence remains preclinical and mechanistic.
Clozapine and Prefrontal Circuit Assay Design
2026-09-28
Clozapine is an atypical antipsychotic medication whose receptor and ERK1/2 effects can help researchers probe prefrontal biology. This article explains how to use it alongside emerging magnetic-stimulation findings without confusing distinct mechanisms or overextending translational claims.
Antiemetics and Renal OCT2/MATE1 Drug Secretion
2026-09-27
George and colleagues compared five 5-HT3 antagonist antiemetics in cell-based assays and found that their inhibition of renal OCT2 and MATE1 varied substantially by compound and transporter. The results identify a potential mechanism for altered renal secretion of organic cation drugs, while remaining in vitro evidence that does not by itself establish clinical drug interactions.